Can ribonucleotide reductase be considered as an effective target for developing antiherpes simplex virus type II (HSV-2) compounds?

Authors:
  • LNLouise M. Nutter
    Louise M. Nutter
  • SGSusan P. Grill
    Susan P. Grill
  • YCYung-Chi Cheng
    Yung-Chi Cheng

Abstract
No abstract available

This publication has 16 references indexed in Scilit: